Pharmacy

PBMs make the argument for DIR fees after a litany of complaints from industry stakeholders.

New public opinion survey about opioid use from Prime Therapeutics has surprising results.

Healthcare executives identify how the industry could be affected if the Aetna-CVS merger goes through.

Analysis from RAND helps frame the potential of biosimilars to reduce spending on biologics.

As genomics continues to evolve, here are five things to know about genetic testing and counseling.

A Physicians Foundation survey gives healthcare executives behind the scenes insight into the physician-patient relationship.

FDA incentives have hastened the development of “orphan drugs” for rare diseases, but some worry that regulators are not always demanding clear evidence for drug efficacy.

With the high efficacy and dire diagnosis, there will be demand for both Kymriah and Yescarta. Here’s how to manage the monetary impact.

CAR-T therapies have high price tags so it’s important to understand your patient population and budget impact.

A University of Massachusetts clinical consulting pharmacist shows how assessing budget implications can be accomplished.

CMS’ 5-Star Rating system requires proactive intervention to improve patient medication adherence, and leaves plans with little room to rest on their laurels.

Pre-drug-approval forecasting and budgeting is increasingly important for payers. Is a safe harbor for manufacturers necessary?

External, non-payer generated data can inform formulary decision-making-if payers know their strengths and weaknesses.

New Yale University research offers stunning findings about drug formulary coverage and prescribing opioids.

The specialty drugs market will see more approvals in 2017 than 2016. Top areas to watch include cancer, multiple sclerosis, and HIV.

Value-based insurance designs for diabetes care improve outcomes, but monetary gains may take years.

Recent and pending drug approvals emphasize the growing importance of niche agents for very specific cancer patient populations.

Here’s a quick guide to the meaning behind Trump’s executive order and decision to stop cost-sharing reduction payments.

The FDA pushes back on new painkiller’s abuse-deterrent claims. Here’s why this is important to the opioid epidemic.

A new study uses population health analytics to identify potential opioid abuse, and the study findings are troubling.

Recently, FDA Commissioner Scott Gottlieb announced the FDA will move to close loopholes in the Orphan Drug Program. Here’s what you need to know.

Consider these five opportunities to help curb one of the biggest public health issues of the year.

An eye-opening Canadian study has surprising findings about the risk of death and antidepressants.

More support for clinical trials and a wider lens for rare diseases in children sets the category on fire.

New physician-administered therapies on the horizon may help rein in the opioid epidemic.